Sarepta already have US$1.6bn in the bank so the closing date of the raising is irrelevant.
Sarepta also have a potential US$1.7bn in milestone payments from Roche if they get the gene therapy approved.. paying ANP a sizeable license fee to help increase the chances of those funds being received seems like good business sense don’t you!!
Also, @waynesworld, delving further into Thrombospodin 1 has got me thinking alot longer term about my investment in ANP. No wonder Graham Mitchell mentioned “assured success”.
Where others have failed will Atl1102 succeed ?, page-795
-
- There are more pages in this discussion • 302 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
